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Thoracic aorta shows with advancing age various changes and a progressive deterioration in structure and function. As a result,
vascular remodeling (VR) and medial degeneration (MD) occur as pathological entities responsible principally for the sporadic
TAA onset. Little is known about their genetic, molecular, and cellular mechanisms. Recent evidence is proposing the strong role
of a chronic immune/inflammatory process in their evocation and progression. Thus, we evaluated the potential role of Toll like
receptor- (TLR-) 4-mediated signaling pathway and its polymorphisms in sporadic TAA. Genetic, immunohistochemical, and
biochemical analyses were assessed. Interestingly, the rs4986790 TLR4 polymorphism confers a higher susceptibility for sporadic
TAA (OR = 14.4, 𝑃 = 0.0008) and it represents, together with rs1799752 ACE, rs3918242 MMP-9, and rs2285053 MMP-2 SNPs,
an independent sporadic TAA risk factor. In consistency with these data, a significant association was observed between their
combined risk genotype and sporadic TAA. Cases bearing this risk genotype showed higher systemic inflammatory mediator
levels, significant inflammatory/immune infiltrate, a typical MD phenotype, lower telomere length, and positive correlations
with histopatological abnormalities, hypertension, smoking, and ageing. Thus, TLR4 pathway should seem to have a key role in
sporadic TAA. It might represent a potential useful tool for preventing and monitoring sporadic TAA and developing personalized
treatments.
1. Introduction
Heart and vascular system, including particularly the large
elastic arteries, that is, the aorta, shows with advancing age
a multitude of changes at different structural and functional
levels [1–5]. As a result, vascular remodeling (VR) andmedial
degeneration (MD) occur [2, 4]. At the macroscopic level,
these pathological entities induce weakening of aorta wall
and a progressive stiffness [2, 4]. Endothelial dysfunction,
increased oxidative stress, inflammatory reaction, inflam-
matory cell infiltration in aortic wall, apoptosis of vascular
smooth muscle cells (VSMC)s, degeneration of aortic media,
and elastin fragmentation and degradation represent their
microscopic alterations [2, 4]. In turn, they can degenerate in
aortic dilatation and aneurysm and increase the onset risk for
complications, that is, aortic dissection and rupture. VR and
MD are the typical pathological entities of several aorta dis-
eases, including the inherited syndromic and familial forms
of thoracic aortic aneurysm (TAA) and the sporadic forms
[6]. Among these, sporadic TAA is becoming a common
and serious health risk because of growing enhance of old
people inWestern populations [7, 8]. Aged population shows
an increased incidence for sporadic TAA with advancing
of years, as recently reported by epidemiological studies
executed in geographic regions with stable populations with
little out- or in-migration, such as in Minnesota and Sweden
[9, 10]. Another determining factor related to the population
ageing is the increased number of hypertensive individuals
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[11]. Hypertension is, indeed, a widely prevalent and impor-
tant risk factor for cardiovascular diseases, including sporadic
TAA, as established by recent guidelines [11].
Sporadic TAA is considered a pathology by unclear
mechanisms [12]. However, current research’s interest is
enormously increasing, even if the literature data about its
genetic, molecular, and cellular mechanisms are inconsis-
tent. In addition, it is growing the opinion to consider
thoracic aortic aneurysms, and particularly the sporadic
forms, as immune/inflammatory diseases with a strong
genetic component [13]. An active participation of both
innate/inflammatory and clonotypic responses has been
evidenced. He and colleagues observed an infiltration of
inflammatory/immune cells in the media and adventitia
from aorta samples of patients with sporadic TAA [14,
15]. Accordingly, we detected a significant high number of
CD3+CD4+CD8+CD68+CD20+ cells in tissue aorta samples
from patients with Stanford type A aortic dissection (TAAD).
A significant role of inflammatory variants in the TAAD risk
was also identified in our study [16].Thus, chronic inflamma-
tion might contribute to the pathogenesis of sporadic TAA.
This also leads to supposing that sporadic TAA may be the
result of a complex combination of factors, including a high
genetic propensity, epidemiology factors, age-related vascular
alterations, hemodynamic stress, chronic inflammation, and
aortic injury. In this complex scenario, the identification of
the pathways activated by these chronic stressors might be
crucial, in order to translate experimental data in clinical new
personalized measures of prevention, diagnosis, treatments,
and management.
In consistency with this suggestion, we propose that
sporadic TAA might be the consequence of an active
stimulation of a particular inflammatory signaling pathway,
the Toll-like receptor (TLR)-4-mediated signaling pathway,
able to recognize both pathogens and endogenous ligands.
An increasing number of studies underlines the weight of
TLR4-mediated signaling pathway in several cardiovascular
diseases (CVD)s [23, 30–36]. In addition, its strong role
in age-related aorta dysfunction, aneurysm’s onset, and its
complications (dissection or rupture) recently is emerging. A
histopathological study demonstrated the TLR4 expression’s
profile in all cells of arterial wall, and particularly in endothe-
lial cells (EC)s and VSMCs. It also evidenced its functional
importance in mediating physiological aorta homeostasis
and maintaining of protection against pathogens and dam-
aging cell molecules, as well as in inducting pathological
aorta phenotypes [23]. Recent experimental investigations
in animal and ex vivo models also emphasises its role
in the vascular aorta alterations (VR and MD) and their
complications, that is, sporadic TAA, by inducing or mod-
ulating increased expression and activation of endothelium
dysfunction and remodeling aorta pathways (i.e., angiotensin
converting enzyme (ACE), endothelial oxide nitric synthase
(eNOs), and metalloproteinase (MMP) pathways) [37–42].
In addition, genetic variants of TLR4-mediated signaling
pathway have been associated with the susceptibility for
several CVDs [30–36]. In particular, polymorphisms of TLR4
gene (NM-138554.1), and particularly the rs4986790 TLR4
polymorphism, have been associated with the risk for several
CVDs and other age-related diseases (i.e., Alzheimer disease,
prostate cancer, and diabetes), even if contrasting results have
been reported [30, 32, 36, 43].
In the light of this current evidence, we sought in the
present study to investigate the potential role of TLR4-
mediated signaling pathway (promoter) in sporadic TAA.
Precisely, we analysed the weight of ten genetic variants
related to TLR4-mediated signaling pathway in disease sus-
ceptibility, evocation of aorta abnormalities, systemic inflam-
mation (arterial-associated senescence secretor phenotype-
AASSP), and vascular biological ageing. Thus, associations
between their combined risk genotypes and typical patho-
logical tissue phenotypes, systemic inflammatory mediator
levels, inflammatory/immune infiltrate, apoptosis of VSMC
cells, tissue MMP-9 amounts, and attrition of telomeres were
also evaluated.
2. Materials and Methods
2.1. Patient Population. Our study included 161 individuals
(127 men (78%) and 34 (22%) women; mean age: 63 ± 10.7)
from Western Sicily enrolled precisely from January 2004
to July 2008 at time of their admission to Cardiac Surgery
Unit of Palermo University Hospital. They were affected by
sporadic TAA and diagnosed through imaging technologies
(i.e., ECHO, CT and MRI) and with localization essentially
in ascending aorta (precisely in aortic sinus and tubular
portion and sometimes only in tubular portion) and in
aortic bulb or both (see Table 1). For the patient’s selection,
histopathological analyses and exclusion criteria for syn-
dromic and familial forms (e.g., Marfan and Ehler’s Danlos
syndromes) and autoimmune connective tissue disorders
were utilised. According to 2010 guidelines, elective or acute
surgical treatment (using wheat operation, Bentall-De Bono
and Tirone David surgical techniques, whenever possible)
and consequent resection were performed after evaluation
of aortic transverse diameter sizes [44, 45]. Their evalua-
tions are reported in detail in the paragraph “Evaluation of
aortic transverse diameter sizes” in Supplementary Material
available online at http://dx.doi.org/10.1155/2014/349476.The
mean of these values was reported in Table 1.
Medical histories pertinent to aortic disease were ob-
tained from patient’s medical records. Thus, demographic
and clinical features, comorbidity conditions, and pharmac-
ological treatments were collected (see Table 1).
2.2. Control Population. The control group consisted of 128
subjects (61 (47%) men and 67 (53%) women; mean age:
61.08 ± 5.83 years), belonging to the same ethnic group of
patients, in order to include in the study a very homoge-
nous population. Ethnicity was confirmed, since parents and
grandparents of both patients and controls were born in
Western Sicily. Controls were in good health according to
their clinical history and blood tests (complete blood cell
count, erythrocyte sedimentation rate, glucose, urea nitro-
gen, creatinine, electrolytes, C reactive protein, liver function
tests, iron, and proteins) (see Table 1). Their demographic
and clinical features, comorbidity conditions, and pharmaco-
logical treatments were collected (see Table 1). Furthermore,
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Table 1: Demographic and clinical characteristics, comorbidity conditions, and pharmacological treatment of 161 patients affected by sporadic
TAA, 128 control subjects, and 30 aorta controls.
Variables Patients
(𝑁 = 161)
Male
(𝑁 = 127)
Female
(𝑁 = 34)
Controls
(𝑁 = 128)
𝑃1
(cases versus
controls)
𝑃2
(male versus
female)
Aorta
Controls
(𝑁 = 30)
Demographic characteristics
Age, mean (SD) 63 (10.7) 63 (11) 64 (9) 61.1 (5.8) 0.834 0.594 63.9 (10.3)
Male sex, number (%) 127 (78) 61 (47)
Female sex, number (%) 34 (22) 67 (53)
Body mass index, mean (SD) 27 (4.3) 26.9 (3.8) 27.5 (5.6) 26.9 (2.9) 0.898 0.963 25.6 (2.9)
Size and location
Size (mm), mean (SD) 53.3 (8) 52.9 (7.5) 55 (9.8) 0 (0) 0.191 0 (0)
Location, number (%): 0 (0) 0.198
Ascending aorta 81 (50) 20 (59) 61 (48)
Aortic Bulb 18 (11) 1 (3) 17 (13.4)
Ascending aorta and Aortic bulb 62 (39) 13 (38) 49 (38.6)
Comorbidity conditions, number (%)
Cardiovascular Ischemic Familiarity 59 (36.6) 48 (38) 11 (32) 34 (27) 0.089 0.7 1 (3.3)
Smoking 73 (45) 67 (53) 6 (18) 66 (51) 0.351 <0.001 3 (10)
Hypertension 127 (78.9) 101 (80) 26 (76) 40 (31) <0.001 0.879 2 (6.6)
Dislipidemy 37 (23) 30 (24) 7 (21) 20 (16) 0.158 0.886 0 (0)
Diabetes mellitus 24 (15) 16 (13) 8 (24) 16 (13) 0.677 0.187 0 (0)
Renal failure 5 (3.1) 4 (3.1) 1 (2.9) 0 (0) 0.168 0.621 0 (0)
Dissection 18 (11) 5 (15) 13 (10) 0 (0) 0.669 0 (0)
Aortic valve pathology, number (%): 0 (0)
Normal 90 (56) 71 (56) 20 (59) 0 (0) 0.766 0 (0)
Prolapse 21 (13) 17 (13) 3 (9) 0 (0) 0 (0)
Vascular calcium fibrosis 50 (31) 39 (31) 11 (32) 0 (0) 0 (0)
Aortic valve dysfunction, number (%):
Normal 32 (20) 26 (20.4) 6 (17.6) 0 (0) 0.91 0 (0)
Faint incontinence 29 (18) 22 (17) 7 (20.4) 0 (0) 0 (0)
Moderate incontinence 34 (21) 28 (22) 6 (17.6) 0 (0) 0 (0)
Severe incontinence 44 (28) 35 (28) 9 (26.4) 0 (0) 0 (0)
Faint stenosis 1 (0.6) 1 (0.8) 0 (0) 0 (0) 0 (0)
Moderate stenosis 2 (1.2) 1 (0.8) 1 (3) 0 (0) 0 (0)
Severe stenosis 19 (11.2) 14 (11) 5 (15) 0 (0) 0 (0)
Atherosclerosis coronary syndrome No (%) 54 (33.8) 45 (36) 9 (26.5) 0 (0) 0.42 0 (0)
Drugs, number (%)
Beta blockers 62 (39) 47 (37) 15 (44) 0 (0) 0 (0)
Central alpha-adrenergic agonists 26 (16) 21 (17) 5 (15) 0 (0) 0 (0)
Sartans 32 (20) 27 (21) 5 (15) 0 (0) 0 (0)
Calcium-channel blockers 47 (29) 38 (30) 9 (26) 0 (0) 0 (0)
ACE inhibitors 66 (41) 55 (43) 11 (32) 21 (16) 0 (0)
Antidiabetic drugs 19 (12) 13 (10) 6 (18) 16 (13) 0 (0)
Antiaggregant drugs 51 (32) 44 (34) 7 (21) 40 (31) 0 (0)
Antidislipidemic drugs 36 (22) 30 (24) 6 (18) 0 (0) 0 (0)
Diuretics 36 (22) 24 (19) 12 (36) 40 (31) 0 (0)
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echocardiography imaging examinations confirmed absence
of any aorta wall histopatological abnormalities in all con-
trols.
In order to detect histopathological abnormalities, con-
trol ascending aortas were obtained from 30 individuals (20
men and 10women,mean age: 63.9±10.3) whodied for causes
unrelated to aortic disease and having no sepsis at death time,
as confirmed by autopsy (see Table 1).
Our study received approval from local ethic committees
and all participants gave their informed consent. Data were
encoded to ensure patient and control protection. All mea-
surements were performed without knowledge about nature
of material.
2.3. Histopathological Assays and Identification of MD Pheno-
types. Histopathological investigations were performed only
in 100 aorta samples obtained from aortic wall of patients
who underwent surgical repair, since some patient’s aortas
showed unsuitable histological conditions. The procedures
used were previously reported in our recent studies [16, 46–
49] and briefly described in online Supplementary Mate-
rial. In addition, the following histological features were
evaluated: (1) fibrosis (defined as an increase in interstitial
collagen); (2) medionecrosis (defined as a focal loss of
smooth muscle cell nuclei in the media); (3) cystic medial
necrosis (defined as mucoid material accumulation); (4)
focal or plurifocal medial apoptosis; (5) elastic fragmentation
(defined as focal fragmentation of elastic lamellae in the
media); (6) amounts of MMP-9; (7) inflammatory/immune
cell infiltration. Histopathological abnormalities of aortic
wall were graded and defined according to the definitions
and grading systems used by Bechtel and colleagues [50] (see
details reported in the section of online SupplementaryMate-
rials and precisely in Figures 1(S) and 2(S).) and previously
described in our recent studies [16, 46–49].
In addition, typical phenotypes were detected as reported
in online Supplementary Material and previously described
in our recent study [49].
2.4. Immunohistochemical Assays. Immunohistochemical
analyses were performed on aorta sections. Specific mono-
clonal antibodies were used, and standard techniques were
performed as described in online Supplementary Material.
2.5. Tunel Testing. For detecting apoptosis, a TdT- (Ter-
minal deoxynucleotidyl Transferase-) mediated X-dUTP
(deoxyuridine triphosphate nucleotides) nick end-labeling
(TUNEL) reaction (“In situ cell death detection kit”, Roche
Diagnostics S.p.A, Milano, Italy) was used and performed
as reported in detail in online Supplementary Material.
Three apoptosis patterns were identified: absent, focal, and
plurifocal medial apoptosis, as evidenced in Figure 2(S) in
online Supplementary Material.
2.6. Semiquantitative Evaluation of MMP-9 by Immunohis-
tochemical Assays. A semiquantitative evaluation of MMP-
9 amount in aortic specimens was performed. Staining was
classified as low, moderate, or high amount, as reported in
Figure 2(S) in online Supplementary Material.
2.7. DNA Samples and Molecular Typing. DNA samples
were obtained by blood samples from case and control
individuals (see online Supplementary Material). They were
genotyped for ten SNPs located in promoter and coding
regions of selected candidate genes codifying molecules
related to TLR4-mediated signaling pathway and with
biological effects able to modulate the susceptibility for
several CVDs, such as sporadic TAA. Information about
these SNPs was acquired from dbSNP NCBI, the ENSEMBL
database (http://www.ensembl.org/index.html), and the
UCSC Genome Browser website (http://genome.ucsc.edu)
and reported in Table S1 of online Supplementary Material.
Genotyping was performed using the procedures illustrated
in online Supplementary Material.
2.8. Inflammatory Plasma Molecule Measurements. Plasma
IL-6, TNF-𝛼, MMP-2, MMP-9, and CRP levels were mea-
sured according tomethod reported in online Supplementary
Material.
2.9. Assessment of Mean Terminal Restriction Fragment
Length. A marker of telomere leukocyte length was deter-
mined using DNA samples of 30 cases and 30 controls
selected randomly, but having the same age and gender. The
procedure used was previously described in the study of
Balistreri and colleagues [51].
2.10. Statistical Analysis. All analyses were performed with R
and Microsoft Excel software. Significant differences among
qualitative variables were calculated by using Pearson 𝜒2 test.
To analyze significant relationships among quantitative vari-
ables, Wilcoxon rank sum test was employed. Furthermore,
odds ratios (OR)with 95% confidence intervals (CI) and their
significancewere calculated. To studymortality betweenmale
and female patients, Kaplan-Meier survival functions were
calculated. Differences between survival curves with a Gehan
test and appropriate Peto & Peto modification were carried
out.
Allele and genotype frequencies were evaluated by gene
count. Data were tested for goodness of fit between observed
and expected genotype frequencies according to Hardy-
Weinberg equilibrium, by 𝜒2 tests. Significant differences
in frequencies among groups were calculated by using 𝜒2
test and appropriate tables (2 × 2 and 3 × 3 tables, etc.,
were appropriate and corrected by Bonferroni). Significant
relationship between genetic variables and pathology riskwas
analysed using quasi-likely hood binomial models.
Analysis of variance (ANOVA) test (corrected by Bon-
ferroni) was also utilised to compare positive inflamma-
tory/immune cells between case and control aorta samples.
Unpaired 𝑡-test (Welch corrected) was, utilised to analyse
positive inflammatory/immune cells between pathological
and normal case aortas. To identify possible correlations
between CD3+CD4+CD8+CD68+ cell number and aorta
aneurysm diameter, nonparametrical Spearman correlation
test was also used. The same test was utilised to evaluate the
correlations between the severity of all examined histopatho-
logical abnormalities and patient features or the major risk
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factors (i.e., age, gender, aortic diameter, hypertension, dia-
betes, and smoking) and to assess the correlations between
the MMP-9 and severity of elastic fragmentation.
Quantitative values of the cytokines, MMPs and CRP,
were expressed as mean ± SD. To assess their differences,
unpaired 𝑡-test (Welch corrected) was utilised. Categorical
variables were compared by chi-square test or Fisher’s exact
test. Their correlations were assessed using Spearman’s rank
correlation. A 𝑃 < 0.05 was considered statistically signifi-
cant.
The difference in mean TRF length between cases and
controls was analysed using an independent sample “𝑡”
test. The difference in mean TRF length in subjects with
different risk factors was analysed using bivariate correlation
for continuous variables and independent samples “𝑡” test for
categorical variable. The independent effect of age, sex, and
other risk factors on themean TRF length was analysed using
a linear regression model controlling for case control status.
3. Results
3.1. Patient and Control Characteristics. We analyzed the
patient and control features summarized in Table 1. The
elevated number of sporadic TAA men (127 versus 34
women) led us to compare all patient features according to
gender. No statistical significant differences were detected,
with exception of smoking (67 male versus 6 female, 𝑃 <
0.001 by Pearson 𝜒2 test, 2 × 2 table; OR 5.16 (1.92–
16.32), 𝑃 = 0.0002 by Fisher test). However, among the
major risk factors, hypertension characterised 79% of all
patients, opportunely treated with medications like ACE
inhibitors and beta-blocker, and so forth, during the follow-
up and after surgery (see Table 1). According to gender, no
significant differences were also observed in evaluating long-
term survival (80 months) after surgery. However, OR was
higher for women (4.5 (3.2–6.9) versus 2.6 (2.2–2.9) formen).
Significant differences were, detected in short-term survival
(30 days). Compared with male patients, females showed
increased 30 day mortality: 9 of 34 female (26%) versus 10
of 127 male (8%) (𝑃 = 0.049 by Gehan test; OR 6.5 (1.5–
6.8), 𝑃 = 0.01 by Fisher test) (see Figure 1). These data
correlated with several clinical conditions observed in the
major female number after surgical repair (data not shown).
Comparisons between patient and control features were also
assessed. No statistical significant differences were detected,
with exception of hypertension (127 versus 40 𝑃 < 0.001 by
Pearson 𝜒2 test, 2 × 2 table; see Table 1).
3.2. Allele Frequencies of the Ten TLR4 Related Pathway SNPs
and Identification of a Combined Risk Genotype Related to
TLR4-Mediated Signaling Pathway. In order to demonstrate
the key role of TLR4-mediated signaling pathway in
the pathophysiology of sporadic TAA and to support our
hypothesis, we compared the allele frequencies of ten selected
SNPs between 161 patients and 128 controls. Significant
differences were only found for the following SNPs:
rs4986790 TLR4, rs333 CCR5, rs2070744 eNOs, rs1799752
ACE, rs3918242MMP-9, and rs2285053MMP-2 (see Table 2).
0.5
0.6
0.7
0.8
0.9
1
0 20 40 60 80
Su
rv
iv
al
Months
Kaplan Meier survival estimation for gender 
Female
Male
Figure 1: Survival in female and male patients after surgery.
Among these, we interestingly observed that the rs4986790
TLR4 polymorphism confers a higher susceptibility for
sporadic TAA (OR = 14.4, 𝑃 = 0.0008) (see Table 2). The
protective +896 G TLR4 allele associated with a low risk of
age-related diseases [32] has a frequency only of 0.3% (1) in
cases versus 4% (11) in controls (see Table 2). In addition,
using a quasi-hood binomial statistical model, we obtained
that the rs4986790 TLR4, rs1799752 ACE, rs3918242 MMP-9,
and rs2285053 MMP-2 SNPs are independent risk factors
for sporadic TAA (𝑃 = 0.001). Considering the biological
effects of these SNPs (see Table S1), we assessed the frequency
of +896ATLR4/DACE/−1562TMMP-9/−735TMMP-2 risk
genotype in cases and controls. By comparing it with fre-
quency of other combinations, combined risk genotype, “high
responder genotype,” was significantly represented in cases
than controls. Indeed, 46 patients were carriers of the com-
bined risk genotype versus 10 controls (𝑃 = 0.000009, by 𝜒2
test; OR = 4.7, 𝑃 < 0.0001 by Fisher’s exact test, see Table 3).
3.3. Evaluation of the Role of +896ATLR4/DACE/
−1562TMMP-9/−735TMMP-2 Combined Risk Genotype
in Influencing the Levels of Systemic Plasma Inflammatory
Mediators. Given the overrepresentation of this combined
risk genotype in patients and its strong role in the
susceptibility (OR = 4.7, see Table 3) for sporadic TAA,
we evaluated its biological effect in influencing the grade
of chronic inflammation. Thus, we assessed the eventual
significant differences in systemic plasma levels (AASSP
levels) of IL-6, TNF-𝛼, CRP, and MMP-2 and -9 between all
patients and all controls.The same analysis was performed in
cases bearing combined risk genotype versus no case carriers
and in case carriers versus control carriers. As reported in
Table 4, we detected significant differences of all systemic
plasma mediators between patients and controls. However,
the very interesting and promising datum was the presence
of higher levels of all mediators examined in cases bearing
combined risk genotype than both cases bearing other
genotypes and control carriers of combined risk genotype,
as illustrated clearly in Table 4. Furthermore, we detected
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Table 2: Allele frequencies of rs4986790 (+896A/G) TLR4, rs333 (Δ32) CCR5 deletion, rs2070744 (−786T/C) eNOs, rs1799752 (D/I) ACE,
rs3918242 (−1562C/T) MMP-9, and rs2285053 (−735C/T) MMP-2 SNPs in 161 S-TAA patients and 128 matched controls (2 × 2 comparisons
between the different groups with odd ratio (OR) and 95% confidence interval).
Candidate
genes
Reference SNP
number Alleles
Patients
(𝑁 = 161)
Matched controls
(𝑁 = 128) 𝑃 (2 × 2 tables) OR (95% CI)
TLR4 rs4986790 +896A 321 99.7% 245 96% 0.0008 14.4 (18.1–112.4)
𝑃 = 0.0008+896G 1 0.3% 11 4%
CCR5 rs333 WT 317 98% 238 93% 0.001 4.7 (1.7–13.1)
𝑃 = 0.001
eNOS rs2070744
Δ32 5 2% 18 7%
0.00007 2.2 (1.5–3.2)
𝑃 < 0.0001
−786T 207 64% 204 80%
−786C 115 36% 52 20%
ACE rs1799752 I 125 39% 141 55% 0.0001 1.9 (1.3–2.6)
𝑃 = 0.0001D 197 61% 115 45%
MMP-9 rs3918242 −1562C 282 88% 241 94% 0.011 2.27 (1.2–4.22)
𝑃 = 0.01
−1562T 40 12% 15 6%
MMP-2 rs2285053 −735C 287 89% 251 98% 0.00005 6.1 (2.3–15.8)
𝑃 < 0.0001
−735T 35 11% 5 2%
All genotypes were in Hardy-Weinberg equilibrium.
Table 3: Frequency of +896ATLR4/DACE/−1562TMMP-9/−735TMMP-2 “high responder” (proinflammatory) genotype between patients
and controls (2 × 2 comparisons between the different groups with odd ratio (OR) and 95% confidence interval).
Subjects +896ATLR4/DACE/−1562TMMP-9/−735TMMP-2“high responder” Other genotypes 𝑃 (2 × 2 Table) OR (95% CI)
Patients (𝑁 = 161) 46 115 P = 0.000009 4.7 (2.7–9.8)P < 0.0001Controls (𝑁 = 128) 10 118
Table 4: Systemic plasma mediator’s levels “AASSP” from patients and controls.
Systemic mediators examined Patients(𝑁 = 161)
Controls
(𝑁 = 128) 𝑃 values
∗
IL-6 (pg/mL) 13.69 ± 2.1 5.1 ± 1.9 <0.0001
TNF-𝛼 (pg/mL) 16.34 ± 1.2 8.1 ± 2.4 <0.0001
CRP (mg/L) 16.86 ± 2.2 5.6 ± 1.3 <0.0001
MMP-2 (ng/mL) 57.5 ± 2.8 13.54 ± 1.24 <0.0001
MMP-9 (ng/mL) 59.8 ± 2.5 12.7 ± 1.6 <0.0001
Systemic mediators examined Patients with high responder genotype(𝑁 = 46)
Patients with other genotypes
(𝑁 = 115) 𝑃 values
∗
IL-6 (pg/mL) 17.66 ± 2.1 9.1 ± 0.9 <0.001
TNF-𝛼 (pg/mL) 16.78 ± 1.2 10.1 ± 2.2 <0.01
CRP (mg/L) 20.13 ± 1.7 12.1 ± 0.5 0.01
MMP-2 (ng/mL) 61.8 ± 3.8 26.54 ± 1.6 <0.0001
MMP-9 (ng/mL) 59.7 ± 3.7 21.7 ± 2.6 <0.0001
Systemic mediators examined Patients with high responder genotype(𝑁 = 46)
Controls with high responder genotype
(𝑁 = 10) 𝑃 values
∗
IL-6 (pg/mL) 17.66 ± 2.1 8.66 ± 2.1 <0.0001
TNF-𝛼 (pg/mL) 16.78 ± 1.2 10.78 ± 1.2 <0.01
CRP (mg/L) 20.13 ± 1.7 6.13 ± 1.7 <0.0001
MMP-2 (ng/mL) 61.8 ± 3.8 18.8 ± 3.9 <0.0001
MMP-9 (ng/mL) 59.7 ± 3.7 12.7 ± 2.7 <0.0001
∗By unpaired 𝑡-test with Welch correction.
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Table 5: Comparison of systemic inflammatory mediator’s levels “AASSP” from controls bearing combined risk genotype versus controls
with other genotypes and between controls bearing +896A TLR4 allele versus controls with +896G TLR4 allele.
Systemic mediators examined Controls with combined risk genotype(𝑁 = 10)
Controls with other genotypes
(𝑁 = 118) 𝑃 values
∗
IL-6 (pg/mL) 8.66 ± 2.1 1.1 ± 0.69 <0.0001
TNF-𝛼 (pg/mL) 10.78 ± 1.2 2.1 ± 1.2 <0.0001
CRP (mg/L) 6.13 ± 1.7 0.9 ± 1.5 <0.0001
MMP-2 (ng/mL) 18.8 ± 3.9 2.54 ± 1.3 <0.0001
MMP-9 (ng/mL) 12.7 ± 2.7 1.7 ± 1.6 <0.0001
Systemic mediators examined Controls with +896ATLR4 allele(𝑁 = 10)
Controls with +896G TLR4 allele
(𝑁 = 118) 𝑃 values
∗
IL-6 (pg/mL) 5.1 ± 0.9 0.9 ± 0.5 <0.0001
TNF-𝛼 (pg/mL) 7.1 ± 0.6 2.1 ± 1.2 <0.001
CRP (mg/L) 4.3 ± 1.1 0.3 ± 1.9 <0.0001
MMP-2 (ng/mL) 10.6 ± 1.8 1.8 ± 0.9 <0.0001
MMP-9 (ng/mL) 8.3 ± 0.7 0.98 ± 1.5 <0.0001
∗By unpaired 𝑡-test with Welch correction.
that higher plasma levels of MMP-2 and -9 levels from cases
bearing combined risk genotype significantly correlated with
the moderate and elevated amounts of MMP-9 detected
reciprocally from their tissue aorta samples (𝑟 = 0.397,
𝑃 = 0.001; 𝑟 = 0.234, 𝑃 = 0.03 by nonparametrical Spearman
correlation test; data not shown). In particular, cases having
combined risk genotype showed a significant association
between increased plasma MMP-9 and MMP-2 levels and
elevated amounts of MMP-9 (𝑃 = 0.006 by 𝜒2 test; data not
shown). Consistent with these data, positive correlations
were detected in the cases with combined risk genotype
between the increased plasma levels of MMP-9 and MMP-2
and elastic fragmentation and the elevated amounts of
MMP-9 observed in their tissue aorta samples (𝑟 = 0.497,
𝑃 = 0.0001; 𝑟 = 0.267, 𝑃 = 0.03, 𝑟 = 0.342, 𝑃 = 0.006,
resp., by nonparametrical Spearman correlation test; data
not shown).
3.4. Assessment of the Biological Effect of +896ATLR4/DACE/
−1562TMMP-9/−735TMMP-2 Combined Risk Genotype,
“High Responder Genotype,” and Alleles of TLR4 Gene in
the Healthy Control Group. In verifying the influence and
the biological effect of combined risk genotype on levels
of systemic inflammatory mediators, and consequently its
role in the occurrence of VR, MD and their complications,
such as sporadic TAA, their quantities were compared
in control carriers versus no control carriers (10 versus
118, as reported in Table 3). As shown in Table 5, this
comparison demonstrated significant differences of all
systemic inflammatory mediators (IL-6, TNF-𝛼, CRP, and
MMP-2 and -9) in controls bearing the high responder
genotype than those with other genotypes. Thus, combined
risk genotype seems to mediate a crucial biological effect on
the levels of systemic inflammatory mediators and, hence, in
the evocation of MD, VR, and sporadic TAA.
We also evaluated the potential significant differences
of levels of systemic AASSP mediators in controls screened
only for the presence of rs4986790 TLR4 polymorphism.
Controls bearing the allele +896G, associated with a blunted
innate/inflammatory response, showed significant reduced
levels of all systemic AASSP mediators than carriers of the
+896A TLR4 allele (see Table 5). Thus, controls with the
TLR4 proinflammatory +896A allele had significant levels of
systemic mediators, but their magnitude was lower than that
observed in controls with the combined risk genotype.
3.5. Detection of the Inflammatory Cell Infiltration in Tissue
Aorta Samples from Patients and Controls and the Examina-
tion of the RoleMediated of the CombinedRiskGenotype. Fur-
thermore, infiltration of lymphocytes and macrophages was
also detected in tissue aorta wall samples from patients, con-
trol aortas, and normal areas from the same TAA tissues. A
significant higher infiltrate of lymphocytes and macrophages
in tissue aortawall samples frompatients comparedwith both
control aortas and normal areas from the same TAA tissues
was observed (see Figure 2). Interestingly, the infiltration of
inflammatory/immune cells was particularly considerable in
the vasa vasorumof adventitia from the aorta patient samples.
In contrast, a very small infiltrate of these cells was observed
in control aortas, which appears to be less significant in
respect to that found in normal aorta TAA areas. CD20+
cell infiltrate was less represented in three groups, even if
significant differences were observed by comparing the three
cohort tissues (see Figure 2). Immunostaining with CD68
antibody also indicated that macrophages were prevalently
present in aortas from TAA patients in respect to control
aortas and normal areas from the same TAA tissues (see
Figure 2).
In order to validate the biological effect mediated of com-
bined risk genotype on the levels of systemic plasma inflam-
matory mediators, we also compared inflammatory/immune
infiltrate between patients bearing high responder genotype
and those with other genotypes. According to encouraging
data obtained on levels of systemic plasma inflammatory
mediators, we assessed a higher inflammatory/immune infil-
trate in tissue aorta samples from patients bearing high
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Figure 2: Morphometric quantification of lymphocytes, T cell
subpopulations, and macrophages in tissue samples of the control
aortas and patients and normal aorta case areas. CD3, CD4, CD8,
CD20, and CD68 positive cells in media and adventitia and in 10
contiguous high-power fields (magnification 400x) were counted
by two independent observers. Significant increased amounts of
CD3+CD4+CD8+CD68+CD20+ cells were observed by comparing
their values among the three groups (by ANOVA test). In particular,
cases showed significant higher numbers of these cells than controls
and normal aorta case areas.
responder genotype than those bearing other genotypes and
control aortas (see Figure 3). Positive correlation was iden-
tified between the number of CD3+CD4+CD8+ CD68+ cells
observed in aorta samples frompatients bearing high respon-
der genotype and the histological abnormalities observed
through histopathological and immunohistochemical assays
and Tunel testing (see Table 6). As reported in Table 6, the
number of CD3+CD4+CD8+ CD68+ cells also correlated
with the increased plasma levels of IL-6, TNF-𝛼, CRP, and
MMP-2 and -9.
3.6. Identification of Typical MD Phenotypes andTheir Poten-
tial Association with Combined Risk Genotype. In addition,
the 46 patients with combined risk genotype showed for the
89% a typical morphological aorta’s phenotype, defined in
our previous study as phenotype III, characterized by ele-
vated cystic MD, plurifocal medial apoptosis, and increased
MMP-9 amount (as reported in online Supplementary Mate-
rial) [42]. Positive correlations were identified between the
severity of histopatological abnormalities characterising this
phenotype and hypertension, smoking, and age (𝑟 = 0.179,
𝑃 = 0.03; 𝑟 = 0.345, 𝑃 = 0.001; 𝑟 = 0.267, 𝑃 = 0.02, resp., by
nonparametrical Spearman correlation test; data not shown).
3.7. Assessment of the Weight of Combined Risk Genotype
in Inducing Vascular Biological Ageing: Analysis of the Gold
Marker of Biological Ageing “Telomere Attrition”. Consistent
with these interesting data, we also evaluated whether the
combined risk genotype can likely have a strong role in
determining vascular senescence and onset of sporadic TAA.
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Figure 3: Morphometric quantification of lymphocytes, T cell
subpopulations, and macrophages in aorta samples of cases with
high responder genotype, other genotypes, and controls. CD3, CD4,
CD8, CD20, and CD68 positive cells in media and adventitia and in
10 contiguous high-power fields (magnification 400x) were counted
by two independent observers. Significant increased amounts of
CD3+CD4+CD8+CD68+CD20+ cells were observed by comparing
their values among the three groups (by ANOVA test). In particular,
cases with high responder genotype had higher numbers of these
cells than controls and cases with other genotypes.
Table 6: Correlations between the number of CD3+CD4+CD8+
CD68+CD20+ cells observed in aorta samples frompatients bearing
combined risk genotype and the histological abnormalities observed
through histopathological and immunohistochemical assays and
Tunel testing and levels of IL-6, TNF-𝛼, CRP, and MMP-2 and -9.
Variables Correlations 𝑃 values∗
Medionecrosis of grade III 0.278 0.02
Cystic-medial change of grade III 0.346 0.001
Elastic fragmentation of grade III 0.467 0.0001
Plurifocal Medial apoptosis 0.333 0.001
Elevated MMP-9 amounts 0.379 0.001
IL-6 0.379 0.003
TNF-𝛼 0.445 0.001
CRP 0.467 0.002
MMP-2 0.578 0.001
MMP-9 0.502 0.001
∗By nonparametrical Spearman correlation test.
To this purpose, we examined the mean of blood leukocyte
telomere length using terminal restriction fragment assay
(TRF test, a southern blot technique) and blood samples from
30 patients and 30 controls, using a procedure described in
two of our recent studies [51]. Thus, we detected that the case
group had a mean TRF length (4.675 ± 0.605 kbp, data not
shown), significantly lower than that observed in the control
group (6.218 ± 0.485 kbp, data not shown). A difference
of 1.543 bp was observed between cases and controls (95%
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confidence interval 68 bp to 201 bp, 𝑃 = 0.001). There was
no significant change in the mean TRF length with age in
both patients and controls (6 bp decrease per year, SD =
4; 𝑃 = 0.25). There was also no significant correlation
between aneurysm size and mean TRF length (𝑃 = 0.46).
There was no significant difference in the mean TRF length
between male and female patients. Comparisons between
mean TRF length and the risk TAA factors including gender,
smoking, hypertension, diabetes, and family historywere also
evaluated. Sex as an independent risk factor did not have any
significant effect on the mean TRF length (𝑃 = 0.76). In
contrast, smoking and hypertension in S-TAA cases were the
only risk factors which were significantly associated with the
mean TRF length (𝑃 = 0.01). S-TAA subjects with smoking
and hypertension history had a significantly shorter mean
TRF length (4.491, SD = 0.237) compared to subjects without
these risk factors (5.997, SD = 0.302), (mean difference 132 bp,
confidence interval 11 bp to 245 bp, 𝑃 = 0.01).
Stratifying the 30 patients having low mean TRF length
for combined risk genotype, we interestingly observed that
85% (versus 8% for controls) were carriers of combined risk
genotype (𝑃 = 0.001 by 𝜒2 test, 2 × 2 table; data not shown)
and had significant higher levels of plasma inflammatory
mediators (IL-6: 13.8 ± 2.3 versus 5.1 ± 1.4, 𝑃 < 0.001; TNF-
𝛼: 15.5 ± 1.4 versus 8.2 ± 1.2, 𝑃 < 0.001; CRP: 18.4 ± 1.3
versus 6.6 ± 2.8, 𝑃 < 0.0001; MMP-9: 59.9 ± 2.8 versus
11.6 ± 1.8, 𝑃 < 0.0001, and MMP-2: 57.8 ± 3.5 versus 13.7 ±
1.9, 𝑃 < 0.0001, resp.; data not shown), increased amounts
of CD3+CD4+CD8+CD68+CD20+ cells than controls and
patients with other genotypes (𝑃 < 0.0001, by ANOVA test
(corrected by Bonferroni)).
4. Discussion
Sporadic TAA is predominantly a silent ailment, until rup-
ture or dissection occur, and insidious in its onset and
progression. Its diagnosis is exclusively based on imaging
technologies (i.e., ECHO, CT, or MRI) [12]. Accordingly,
it is very crucial to early predict, diagnose, and treat
sporadic TAA, characterised by lack of medical optional
treatments and disease biomarkers, such as blood tests.
Blood tests might consent to detect in general population
individuals at sporadic TAA risk, to monitor its progression
and predict complications. To this purpose, it should be
crucial understanding cellular and molecular mechanisms
and genetic risk factors. Recently, it has been suggested that
aortic aneurysms, and particularly the sporadic forms, are
immune diseases with a strong genetic component [13]. In
particular, a particular involvement of chronic inflammation
is emerging. We have evidenced this crucial aspect of the
complex pathophysiology of this disease in our recent studies
[16, 46–49]. In patients with TAAD, we observed high levels
of immune/inflammatory cells and a significant associa-
tion of some inflammatory polymorphisms with the TAAD
susceptibility. In line with this, He and colleagues recently
observed an increased immune/inflammatory infiltrate in
aorta samples of patients with sporadic TAA [14, 15]. This
is leading to identify the inflammatory pathways, which
might operate as key link between the onset of sporadic
TAA and immune system. Their recognition should be very
imperative in order to translate experimental data in clinical
new personalized measures of TAA prevention, diagnosis,
treatments, and management.
Considerable and convincing evidence links the patho-
physiology of atherosclerosis, cardiac dysfunction, congestive
heart failure, and other vascular diseases with the TLR-4-
mediated signaling pathway, as amply stressed by Frantz
and colleagues [31]. Recently, the group of Pasterkamp also
provided an overview of the endogenous molecules, released
under cellular cardiovascular stress and damage, which can
trigger innate immunity via TLR-4-mediated signaling path-
way in CVDs [33]. In the specific case of sporadic TAA,
recent experimental investigations in animal and ex vivo
models also emphasise its role in the vascular aorta alterations
(VR and MD) and their complications, such as sporadic
TAA, by evocating or modulating increased expression and
activation of endothelium dysfunction and remodeling aorta
pathways [23, 37–42]. On the other hand, Pryshchep and
colleagues demonstrated the TLR4-mediated signaling path-
way expression in all cells of arterial wall and particularly
in ECs and VSMCs. In addition, they also evidenced its
functional importance in both mediating physiological aorta
homeostasis andmaintaining protection, as well as in induct-
ing pathological aorta phenotypes, that is, VR and MD
[23]. Furthermore, Song and colleagues demonstrated that
signaling via TLR4-mediated signaling pathway and its signal
adaptors, that is, MyD88, is responsible for the age-elevated
basal IL-6 response using VSMCs from aged 𝑇𝐿𝑅4−/− and
𝑀𝑦𝑑88
−/− mice [37]. Eissler and colleagues observed an
increased hypertension-related expression of TLR4-mediated
signalling pathway in vascular cells of untreated hyperten-
sive rats [38]. The group of Golzales-Ramos underlined
that circulating Heat Shock protein 70, associated with an
increased cellular aorta’s damage, regulates the profibrotic
response of human aorta SMCs through increased trans-
forming growth factor type-1 (TGF-1) expression, evocated
by TLR4-mediated signaling pathway [39]. In addition, Li
and colleagues reported the role of TLR4-mediated signaling
pathway in regulating the MMP-9 expression in human
VSMCs [40]. Bucci and colleagues recently emphasized as the
vascular thoracic aorta homeostasis and its alteration in rats
is based on the activity of TLR4-mediated signaling pathway
and its cross talk with other stress and stretch pathways,
that is, ACE, eNOs, and MMP pathways [41]. Furthermore,
a recent study demonstrated in apolipoprotein E-deficient
mice that it is possible to limit the inflammatory process by
blocking TLR4/c-Jun N terminal kinase signaling pathway
with Rosiglitazone in the initiation stages of aortic aneurysm
development [42].
This encouraging and increasing evidence, fruit preva-
lently of animal investigations, and our recent data on TAAD
[16, 46, 48], led us to analyze the potential role of genetic
variants related to TLR4-mediated signaling pathway in the
complex pathophysiology of sporadic TAA. Until now, no
literature data exist about their role in sporadic TAA. Thus,
our study represents the first report which, through a human
ex vivo study approach, evidenced as some polymorphisms
related to TLR4-mediated signaling pathway significantly
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modulate the sporadic TAA risk: rs4986790 TLR4, rs333
CCR5, rs2070744 eNOs, rs1799752 ACE, rs3918242 MMP-
9, and rs2285053 MMP-2 polymorphisms. Among these, the
rs4986790 (+896A>G) TLR4 polymorphism confers a higher
susceptibility for sporadic TAA (OR = 14.4, 𝑃 = 0.0008).
However, it represents an independent risk TAA factor for
sporadic TAA, as well as the rs1799752 ACE, rs3918242
MMP-9, and rs2285053 MMP-2 SNPs. Thus, we assessed
whether their combined genotype constitutes a risk profile.
A significant overrepresentation of their combined risk geno-
type (+896ATLR4/DACE/-1562TMMP-9/-735TMMP-2) was
observed in cases than controls (46 versus 10, 𝑃 < 0.000009)
by comparing it with frequency of other combinations. In
addition, it was associated a significant risk for sporadic
TAA (OR = 4.7; 𝑃 < 0.0001). Cases bearing combined risk
genotype showed higher systemic inflammatory mediator
levels than those with other genotypes and control carriers.
In particular, they had higher plasma levels of MMP-9 and
-2 which correlated with the amounts of MMP-9 and elastic
fragmentation observed in their tissue aorta samples. A
higher chronic inflammatory infiltratewas also found in cases
bearing combined risk genotype, which positively correlated
with histological abnormalities and levels of mediators. In
addition, they showed in their tissue aorta samples a typical
morphological phenotype, characterized by elevated cystic
MD, plurifocal medial apoptosis, and increased MMP-9
amounts, and defined in a previous study as phenotype III
[42]. Furthermore, we detected that combined risk genotype
influences vascular biological ageing, evaluating the gold
standard ageing marker, the telomere length, in a small
number of cases and controls, selected randomly, but having
the same age and gender. It characterized the 85% of the cases
examined, which had lower telomere length, higher levels
of mediators, increased amount of chronic inflammatory
infiltrate. This results concord with the preliminary data
reported in a previous study and the recent literature reports
[51–53].
These interesting results led us to evaluate the biological
effect of the combined risk genotype. Thus, we analysed
the levels of systemic mediators in healthy group. Controls
bearing high responder genotype showed higher levels of sys-
temic mediators than control carriers of only the rs4986790
TLR4 polymorphism.These results are in agreement with our
previous data [54, 55]. Indeed, in clarifying and confirming
the biological effects of rs4986790 TLR4 polymorphism and
its role in the pathophysiology of age-related diseases, includ-
ing CVDs, Alzheimer disease, prostate cancer, diabetes, and
longevity, we assessed the levels of IL-6, TNF-𝛼, IL-10, and
eicosanoids in LPS-stimulated whole blood samples in vitro
of 50 young healthy Sicilians, screened for the presence
of rs4986790 TLR4 and −765G>C PTGS2, −1708G>A 5-
Lo polymorphisms [54]. Significantly higher levels of both
proinflammatory cytokines and eicosanoids were observed
in individuals bearing the rs4986790 TLR4 polymorphism.
However, theirmagnitude significantlywasmore increased in
individual’s carriers of their combined genotype. In addition,
significantly lower levels of inflammatory mediators were
observed in carriers bearing the TLR4 mutation (the +896G
allele), whereas the anti-inflammatory IL-10 values were
higher [54]. The same results were detected in this study in
the controls carriers of the +896G TLR4 allele. Thus, these
data strengthen our suggestion, stressed for other age-related
diseases including Alzheimer disease and prostate cancer,
that polymorphisms related to TLR4-mediated signaling
pathway may have a major influence on the pathophysiology
of a disease, such as sporadic TAA, when they operate in
combination to create a “risk profile” [56, 57].
5. Limitations and Conclusions
In the complex, our data seem to suggest the strong rel-
evance of TLR4-mediated signaling pathway in inducing
MD, age related VR, and their complications, such as spo-
radic TAA. On the other hand, our findings emphasise
as a combined risk genotype associated of TLR4-mediated
signaling pathway are able to modulate the grade of aorta
age-related phenotypical, histological, and systemic abnor-
malities and consequently vascular aorta ageing, onset, and
progression of sporadic TAA. They also lead us to sug-
gest that this signaling pathway might also be an optimal
target for new therapeutic treatments able to retard or
block the typical aorta age-related changes which determine
endothelial dysfunction, MD, and VR. This might open
new perspectives for the prevention of both aortic VR and
MD and sporadic TAA, by using combined risk genotype
(+896ATLR4/DACE/−1562TMMP-9/−735TMMP-2) as opti-
mal genetic biomarker for the earlier detection of this silent
pathology in preliminary phases and to treat with different
and specific therapies depending on individual’s genotypes.
Consequently, it also leads to view vascular ageing as a
modifiable risk factor, particularly for aortic disease. In the
specific case of sporadic TAA, the therapeutic potential of
TLR4-mediated signaling pathway might be defined through
the use of its agonists or antagonists, whose effects have
been prevalently experimented in mice, rats, and cultures
as reported in literature [35]. This might consent to reduce
chronic age-related inflammation and limit the dysfunction
of ECs and endothelial progenitor cells (EPCs), which move
towards injured endothelium or inflamed tissues and incor-
porate into foci of neovascularisation, thereby improving
blood flow and tissue repair [58–60]. On the other hand,
a recent investigation reports the involvement of TLR4-
mediated signaling pathway in maintaining the stem cell
phenotype of EPCs and enlarging this population [61]. This
finding reveals a novel aspect of the multiple-faced TLR-
4-mediated signaling pathway biology, and it may open
new prospects for using TLR4 agonists in promoting the
production of EPCs for clinical use. In addition, recent
research underlines that miRNAs might play important
roles in this scenario, modulating TLR-4-mediated signaling
pathway activation [62]. MiRNAs seem, indeed, to have two
opposite roles: TLR-4-mediated pathway activation and NF-
𝜅B signaling inhibition, in a complex scenario where low
and chronic inflammation prevails, likely also sustained by
cell senescence secretome.MiRNAs inhibition effect probably
belongs to the different levels of anti-inflammatory pathways
which have evolved to abate TLR-4 signaling to prevent cell
and aorta destruction [62].
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Figure 4: Our model about the pathophysiology of sporadic TAA, the model of the pathway from the double-face. The major risk factors,
hypertension, age, and smoking, induce an increased production of reactive oxygen species (ROS) [17–19] and an upregulation of local renin-
angiotensin system [16] and the tissue injury, initially involving ECs and subsequently VSMCs. This determines the release of some damage-
related products and proteins (i.e., heart shock proteins (HSPs), high-mobility group box-1, low molecular hyaluronic acid, fibronectin
fragments, and others), called danger-associated molecular patterns (DAMPs) [20]. DAMPs alert innate/inflammatory immune system
interacting with TLR4mediated signaling pathway, able to recognize both pathogens and endogenous ligands [21, 22]. Originally described as
part of the first-line defense against Gram-negative bacteria, the best knownmember of TLRs, the TLR4, expressed on leukocytes and a large
array of tissue and cell types, such as all aortic wall cells (particularly ECs and VSMCs), responds to these signals [23]. As a consequence,
TLR4 activates and triggers an inflammatory response [24–28]. In turn, this determines a typical phenotypic switching of EC and VSMC
cells due to activation of stress and stretch pathways accompanied by their dysfunction and senescence [27, 28]. In particular, it implies
a differential change in their gene expression profile due prevalently of activation of Nuclear Factor-𝜅B (NF-𝜅B) transcription factor and
followed by production and release of the so-called arterial-associated senescence secretor phenotype (AASSP) characterized by numerous
inflammatory mediators, mitotic and trophic factors, proteoglycans and metalloproteinases (MMP)s, such as MMP-2 and -9, and vasoactive
molecules [17, 24–29]. In addition, this also induces the reduction of nitric oxide (NO) [28]. This complex scenario results in modifications
of vascular tone and permeability and degradation of components of extracellular matrix (ECM) and elastic fragmentation. VR and MD are,
hence, evocated, which can evolve in aneurysm, dissection and rupture of aorta wall [17].
Based on our findings, we also suggest another possible
therapeutic intervention to apply in the preclinical phase
in subject’s carriers of combined high risk genotype to the
aim to retard to limit the onset and progression of the
vascular ageing and its complications, such as sporadic TAA.
Precisely, we propose antibody-mediated stimulation of TAM
receptors involved in the inhibition of the inflammatory
response [29]. The sequential induction of this pathway
and its integration with upstream TLR and cytokine signal-
ing networks may impact the evocation of the release of
inflammatory mediators limiting the inflammatory response
and consent to modulate the telomere/telomerase system
reducing the senescence of both the aorta wall cells and the
EPCs able in repairing aorta injury [29]. On the other hand,
patients with CVDs exhibit a reduced EPC number and
function [63–65]. It has become increasingly apparent that
these changes may be effected in response to enhanced
oxidative stress, possibly as a result of systemic and localized
inflammatory responses. Recent studies suggest that inflam-
mation and oxidative stress modulate EPC bioactivity [63–
65].
The weight of our findings and suggestions might be
certainly implemented validating them in a larger sample
size, even if our data are the result of a relatively small sample
and a very homogenous population. In addition, gene expres-
sion analyses, immunohistochemical TLR4 quantification,
and soluble TLR4 level detection represent further objectives
of our future studies. They should consent to translate with
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major emphasis our promising data in personalized treat-
ments of a pathology, the sporadic TAA, which clinically and
predominantly is silent, until rupture or dissection occurs,
and insidious in its onset and progression. Furthermore,
until now its diagnosis is also exclusively based on imaging
technologies.
Finally, our obtained data led us to postulate a potential
model about the pathophysiology of sporadic TAA, which
might be defined as model of the signaling pathway from the
double-face, given its features (see Figure 4).We foretell that it
can lead several researchers to perform investigations focused
to clear the complex puzzle of this pathology.
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